Hi, everybody. I'm Nicola Tangen, the CEO of the Norwegian Soan Wealth Fund.

And today I am in particularly good company with David Ricks, the CEO of the pharma giant Ella Lilly.

Now, Ella Lili is spearheading, as you may know, the weight-reducing drug revolution.

We own more than 1% of the company, totaling $8 billion. Big thanks for coming, Dave.

Great to be with you.

Now, the GLP 1 drug sends shock waves through world, and now they seem to be curing everything

from alcoholism to Alzheimer.

So why are these drugs so efficient?

Yeah.

Well, it's certainly been an exciting time for the company, but also for medical science,

because this is actually not a very new idea to

stimulate GLP1. Lilly launched the first GLP1 agonist in 2006, so almost 20 years ago.

But it's, I think, a good example of how the technology in medicine works is that oftentimes

we know the sort of the major theme, but making a molecule,

making a medicine that behaves with properties that can achieve optimal outcomes, takes time

and effort. And we're now on our, really our third generation of these drugs with tersepotide,

which is a dual acting.

So it's gLP plus gip, two different gut hormones.

You know, I think by making drugs that were flat and lasted a long time and then we could dose a little higher, we've discovered that we are not just affecting blood sugar and other

metabolism factors, but affecting probably the

brain and the desire center.

But when you discovered it in 2005, 2006, it was more like a side effect, wasn't it?

...